| 발표일자: |
2015년 11월 6일(금) ~ 11월 8일(일) |
| 발표번호: |
P(e-poster)-059 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| 신생혈관 나이관련황반변성에서 유리체내 라니비주맙 주입 치료 후 망막색소상피파열 |
| 건양대학교 의과대학 김안과병원 안과학교실 명곡안연구소 |
| 유슬기(1),조한주(2),김형석(3),한정일(4),유영주(5),조성원(6),이태곤(7),김종우(8) |
|
목적 : To evaluate the risk factors for retinal pigment epithelium (RPE) tears after intravitreal ranibizumab injections in neovascular age-related macular degeneration (nAMD) and to determine the efficacy of continued ranibizumab treatment after RPE tears.
방법 : A total of 407 treatment-naïve eyes (377 patients) with nAMD were included. All patients were treated with an initial series of three monthly loading injections, followed by further injections as required. Baseline characteristics and pigment epithelial detachment (PED) lesion features were evaluated as potential risk factors for RPE tear. The visual and anatomical outcomes after treatment during 12 months were also evaluated.
결과 : By 12 months, RPE tears developed in 32 eyes (7.9%). PED height was associated with a higher risk of RPE tear (P=0.018). Fibrovascular PED compared with serous PED had a higher risk of developing tears (P=0.042), and typical nAMD and retinal angiomatous proliferation had a higher risk of developing tears compared with polypoical choroidal vasculopathy (P=0.033). Mean best-corrected visual acuity of RPE tear patients showed no significant improvement after treatment at 12 months; however, patients with RPE tears without foveal involvement (19 eyes) showed significant BCVA improvement (P=0.034)
결론 : PED type and nAMD subtype are associated with the development of RPE tears following intravitreal ranibizumab injections. Continued ranibizumab therapy after RPE tear development can maintain visual acuity when the fovea is not involved.
|
| |